1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Antidiabetics Market Analysis By Product (Insulin, Biguanides, Thiazolodinediones, GLP-agonists, Sulphonylureas, DPP-4 inhibitors, SGLT-2, Alpha-glucosidase Inhibitors, Meglitinides) And Segment Forecasts To 2020

Antidiabetics Market Analysis By Product (Insulin, Biguanides, Thiazolodinediones, GLP-agonists, Sulphonylureas, DPP-4 inhibitors, SGLT-2, Alpha-glucosidase Inhibitors, Meglitinides) And Segment Forecasts To 2020

  • May 2016
  • -
  • Grand View Research
  • -
  • 75 pages

Summary

Table of Contents

Global antidiabetics market is expected to reach USD 84.13 billion by 2020. Growing prevalence of diabetes is the primary driver of this market. Growth in prevalence of disease causing lifestyle disorders such as irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. Introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Further key findings from the study suggest:

Long acting insulin was the leading product segment in 2013 and is expected to grow at the CAGR of over 15.0% during the forecast period. The introduction of advanced products, high prices associated with these products and the phasing out of human insulin are some key factors attributing for its large share.
Rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina and Onglyza on account of their once daily dosage regimens and safety profiles catalyzed the growth of this market.
North America was the most matured antidiabetics market in 2013 accounting for over 43.0% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.
Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.
Some key market players of antidiabetics include Sanofi Aventis, Takeda Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals Inc., Merck & Co. Inc., Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics and Pfizer.
The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.
For the purpose of this study, Grand View Research has segmented the global antidiabetics market on the basis of product and region:

Global Insulin Product Outlook (Revenue, USD Million, 2012 – 2020)
- Rapid acting
- Long acting
- Premixed
- Premixed analog
- Short acting
- Intermediate acting
Global Antidiabetics Product Outlook (Revenue, USD Million, 2012 – 2020)
- Alpha-glucosidase inhibitors
- Biguanides
- Sulphonylureas
- GLP-1 agonist
- Meglitinides
- DPP-4 inhibitors
- SGLT – 2
- Thiazolodinediones
Antidiabetics Regional Outlook (Revenue, USD Million, 2012 – 2020)
- North America
- Europe
- Asia Pacific
- RoW

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Needle-Free Diabetes Management Market Size, Share, Development, Growth and Demand Forecast to 2025 - Industry Insights by Device Type

Global Needle-Free Diabetes Management Market Size, Share, Development, Growth and Demand Forecast to 2025 - Industry Insights by Device Type

  • $ 5100
  • Industry report
  • February 2017
  • by P&S Market Research

Market Overview Needle-free diabetes management refers to treatment, diagnosis and monitoring of diabetic patients without using needles. Needle-free diabetes management devices are used for injecting ...

Future of Diabetes Care Paradigms, Forecast to 2022

Future of Diabetes Care Paradigms, Forecast to 2022

  • $ 4950
  • Industry report
  • March 2017
  • by Frost & Sullivan

Innovations to Disrupt Diabetes Wellness, Diagnosis, Monitoring, and Therapy Diabetes management is on the verge of being disrupted by innovative technologies such as artificial pancreas, non-invasive ...

Opportunity in the Indian Anti-Diabetic Pharmaceuticals Market - 2017

Opportunity in the Indian Anti-Diabetic Pharmaceuticals Market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • April 2017
    28 pages
  • Therapy  

  • United States  

View report >

Biguanide Market in India

  • April 2017
    3 pages
  • Biguanide  

    Dermatological ...  

  • India  

View report >

Insulin Market in the US

  • March 2017
    7 pages
  • Insulin  

    Antidiabetics  

View report >

Related Market Segments :

Antidiabetics

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.